Your Location：
Home >
Browse articles >
Cost-Effectiveness of Denosumab for Treating Bone Metastases from Solid Tumors: A Systematic Review (2017-2023)
Chinese Medical Sciences Journal   Vol. 40, Issue 3, Pages: 219-231(2025)
Review Article | Updated：2025-10-14

    • Cost-Effectiveness of Denosumab for Treating Bone Metastases from Solid Tumors: A Systematic Review (2017-2023)

      Enhanced Publication
    • “In a systematic review, researchers assessed the cost-effectiveness of denosumab for bone metastasis treatment, providing evidence-based insights to guide healthcare policy decisions. The majority of studies support denosumab as a more cost-effective treatment option for bone metastases in solid tumors compared to zoledronic acid.”

    • DOI：10.24920/004368    

      CLC：

    • Received：22 April 2024，

      Accepted：11 July 2025，

      Published Online：29 September 2025，

      Published：30 September 2025

    Scan QR Code

  • Wang Cong,Liu Jin-Yu,Wan Min,et al.Cost-Effectiveness of Denosumab for Treating Bone Metastases from Solid Tumors: A Systematic Review (2017-2023)[J].Chinese Medical Sciences Journal,2025,40(03):219-231. DOI： 10.24920/004368.

  •  
  •  

0

Views

7

Downloads

0

Scopus

PlumX

>
Alert me when the article has been cited
Submit
Outline
No Sections

Related Articles

Application of Assessment Scales in Palliative Care for Glioma: A Systematic Review
Diagnostic Accuracy of Computerized Bowel Sound Analysis with Non-Invasive Devices for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

Related Author

Ru-Xu You
Xiao-Peng Guo
Yue-Kun Wang
Ya-Ning Wang
Ting-Yu Liang
Jun-Lin Li
Wen-Lin Chen
Ya-Ning Cao

Related Institution

Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University
Palliative Care Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Eight-year Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
China Anti-Cancer Association Specialty Committee of Glioma
0